linjc16/ctgov huggingface dataset:
Drainage Seton With Flap Versus EAS Preserving Seton in Treatment of Transsphincteric Anal Fistula

Study Overview
=================
Brief Summary
-----------------
Patients with high trans-sphincteric anal fistula will be randomized to one of two equal group: group 1 will have drainage seton with mucosal advancement flap and group 2 will undergo external anal sphincter sparing seton

Official Title
-----------------
Drainage Seton Around the External Anal Sphincter With Mucosal Advancement Flap Versus External Anal Sphincter Preserving Seton in Treatment of Trans-sphincteric Anal Fistula

Conditions
-----------------
Anal Cancer

Intervention / Treatment
-----------------
* Procedure: Drainage seton with flap
* Procedure: EAS sparing seton


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients suffering from high trans-sphincteric anal fistula Exclusion Criteria: Acute sepsis. Specific cause of fistula e.g. Crohn's disease Strictured anorectum. Any degree of incontinence Recurrent anal fistula. Low anal fistula. Previous anorectal surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Drainage seton with flap<br>Drainage seton will be put around the external anal sphincter with mucosal advancement flap | Procedure: Drainage seton with flap<br>* Seton is placed around the external sphincter then mucosal advancement flap will be constructed<br>|
| Experimental: EAS sparing seton<br>Rerouting of the seton around the internal anal sphincter sparing the external sphincter will be done | Procedure: EAS sparing seton<br>* Rerouting of the seton around the internal sphincter only sparing the external sphincter<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fecal incontinence | Number of patients who develop fecal incontinence as assessed by Wexner Incontinence score | 12 months after surgery |
Lung Nodule Characterization by Artificial Intelligence Techniques

Study Overview
=================
Brief Summary
-----------------
Management of incidental lung nodule is difficult and mainly based on simple morphometric characteristics such as maximum size and shape. Radiomics could play a role in simplifying this management by orientating towards a benign or a malignant origin, by comparing advanced characteristics to a large database of lung nodules. The primary purpose is to evaluate the performances of a novel tool based on radiomics to characterize incidental lung nodules, discovered on computed tomography. The secondary objectives are: to evaluate the variation in the performances of the software based on various technical aspects of the CT, such as radiation dose, reconstruction algorithm, type of scanner,… to compare the performances of this software to those of expert readers, to analyze the potential impact of this software on patient's management.

Official Title
-----------------
Lung Nodule Characterization by Artificial Intelligence Techniques

Conditions
-----------------
Incidental Lung Nodule

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient (at least 18 years old); With a chest CT acquired between Jan 1 2012 and Oct 1 2018 at the Strasbourg University Hospital; CT being available over the PACS and exhibiting at least one lung nodule; Patient having given its authorization for the exploitation of his medical data for this research. Exclusion Criteria: Patient having expressed direct opposition to participation in this study; Patient under juridical protection; Patient under tutelage or guardianship.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the performances of a novel tool based on radiomics to characterize incidental lung nodules, discovered on computed tomography. | The study concerns patients who performed a chest CT scan at Strasbourg University Hospitals between 01/01/2012 and 01/10/2018 | he period from January 1st, 2012 to October 01, 2018 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Solitary Pulmonary Nodule, Multidetector Computed Tomography, Artificial Intelligence
Impact of PD1-lymphocytes in Bronchoalveolar Lavage of Patients With Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The aim of this trial is to assess PD1-lymphocytes in bronchoalveolar lavage in patients with lung cancer, ILD and asthma.

Detailed Description
-----------------
In this trial, 20 patients with lung cancer, 10 patients with asthma and 10 patients with interstitial lung disease who have to undergo bronchocospy for medical reasons are enrolled. In each patient, bronchoalveolar lavage is performed to assess PD1-lymphocytes.

Official Title
-----------------
Impact of PD1-lymphocytes in Bronchoalveolar Lavage of Patients With Lung Cancer

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: bronchoalveolar lavage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >18 years patients with lung cancer, asthma or ILD and indication for bronchoscopy for medical reasons Ability to provide informed consent Exclusion Criteria: acute excacerbation in patients with asthma or ILD endoluminal tumor growth or penumonia in patients with lung cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with lung cancer<br>In lung cancer patients with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes. | Diagnostic Test: bronchoalveolar lavage<br>* Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.<br>|
| Patients wiht interstitial lung disease<br>In patients with interstitial lung disease with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes. | Diagnostic Test: bronchoalveolar lavage<br>* Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.<br>|
| Patients with asthma<br>In patients with asthma with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes. | Diagnostic Test: bronchoalveolar lavage<br>* Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess and compare PD1-lmyphocytes in bronchoalveolar lavage in patients with malignant and benign lung diseases to evluate their impact in lung cancer patients |  | 6 months |
Ghrelin, Growth Hormone and Growth Factors at High Altitude

Study Overview
=================
Brief Summary
-----------------
Regulation of ghrelin, growth hormone and growth factors at high altitude and their change during ascent to high altitude has not been studied in depth yet. The study includes 33 volunteers (12f) investigated at sea level, 4 days after ascent to 3440m and 14 days after ascent to 5400-5900m. The investigators hypothesized that during ascent growth hormone levels would increase to compensate for the higher energy needs at high altitude.

Conditions
-----------------
Healthy, Growth Hormone

Intervention / Treatment
-----------------
* Other: exposure to high altitude


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy and good physical fitness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| probands<br> | Other: exposure to high altitude<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ghrelin, growth hormone, insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP1), IGF binding protein 2 (IGFBP2), IGF binding protein 3 (IGFBP3), acid-labile subunit (ALS), insulin, prolactin |  | 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mountain medicine, ghrelin, growth hormone, hypoxia, physiology of hormonal adaptation to high altitude
Comparison of Lingualized and Full Bilaterally Balanced Articulation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find the difference between patient satisfaction, masticatory performance and cost between two occlusal schemes for complete denture prosthodontics.

Detailed Description
-----------------
Two occlusal scheme applied to complete denture prosthodontics has been compared in RCT. This will have clinical benefit for deciding which occlusal scheme is better according to patient conditions. It will also have impact on dental educational curriculum.

Official Title
-----------------
A Randomized Clinical Trial Comparing Lingualized and Full Bilaterally Balanced Articulation for Complete Dentures

Conditions
-----------------
Jaw, Edentulous

Intervention / Treatment
-----------------
* Procedure: lingualized occlusion
* Procedure: Full Bilaterally Balanced Articulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: edentulous both maxilla and mandible, asking for new denture fabrication Exclusion Criteria: psychiatric problem those who have difficulty answering the questionnaire oral cancer radiation experience
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lingualized<br>complete denture fabricated by lingualized occlusion scheme | Procedure: lingualized occlusion<br>* occlusal surface arranged by lingualized occlusion<br>* Other names: e-ha artificial teeth, shofu porcelain teeth;|
| Placebo Comparator: Full Bilaterally Balanced Articulation<br>complete denture fabricated by Full Bilaterally Balanced Articulation scheme | Procedure: Full Bilaterally Balanced Articulation<br>* occlusal surface arranged by Full Bilaterally Balanced Articulation<br>* Other names: Shofu Ace Posterior;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient satisfaction on 100mm visual analogue scale |  | 6month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment cost |  | 6month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
complete dentures, patient satisfaction, treatment cost
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder

Study Overview
=================
Brief Summary
-----------------
The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) scores versus baseline

Official Title
-----------------
A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder

Conditions
-----------------
Schizophrenia, Psychotic Disorders

Intervention / Treatment
-----------------
* Drug: ziprasidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary diagnosis of schizophrenia or schizoaffective disorder, using DSM-IV criteria. Currently receiving either haloperidol, olanzapine or risperidone within -/+ 25% of the recommended daily dose (as delineated by the medication's package insert Exclusion Criteria: Resistance to conventional antipsychotic drugs With antipsychotic agents other than olanzapine, risperidone or haloperidol at start of treatment regimen within 12 hours prior to first dose of study drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ziprasidone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary efficacy variable will be change from baseline in Brief Psychiatric Rating Scale (BPRS) total score |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline In Clinical Global Impression Severity (CGI-S) |  |  | 
| Clinical Global Impression Improvement (CGI-I) |  |  | 
| Change From Baseline In Positive and Negative Syndrome Scale (PANSS) Total |  |  | 
| Change from baseline in scores on the Montgomery-Asberg Depression Rating Scale (MADRS) |  |  | 
| Change from baseline in scores on the MADRS Without Items 4, 5 |  |  | 
| Change from baseline in Global Assessment of Functioning (GAF) |  |  | 
| Change From Baseline In Drug Attitude Inventory (DAI) |  |  | 
| Change From Baseline In Weight |  |  | 
| Change From Baseline In Prolactin And Lipid Levels |  |  | 
| Change From Baseline in Modified Simpson Angus Scale (m-SAS) Total Score |  |  | 
| Change From Baseline in Barnes Akathisia Scale (BAS) |  |  | 
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)- Movement Ratings Total Score |  |  | 
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)- Global Judgment Of Severity Total Score |  |  |
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the normal functioning of the brain. In subjects with Alzheimer's disease, the level of ACh is greatly reduced. Currently, there are three commonly prescribed drugs used for treating the symptoms of Alzheimer's disease by helping to maintain the level of ACh in the brain. This study will evaluate how much each of these drugs changes the levels of certain brain chemicals that are known to, or may play an important role in, Alzheimer's disease and its symptoms.

Official Title
-----------------
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Drug: Rivastigmine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of mild to moderate Alzheimer's disease Must be able to swallow capsule/tablet Must have a caregiver who is available to attend all study visits Exclusion Criteria: Digestive problems related to peptic ulcer Experienced a heart attack or stroke in the last 6 months Serious/unstable asthma or severe pulmonary (lung) disease On current treatment with a blood thinner

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rivastigmine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in specific brain enzyme activity from baseline to week 13 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlate changes in specific brain enzyme activity at week 13 to cognition and behavior |  |  | 
| Changes in levels of protein biomarkers in Alzheimer's disease and neurodegeneration from baseline to week 13 |  |  | 
| Correlate changes in specific brain enzyme activity after 13 weeks treatment to changes in global functioning at 13 and 26 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimer's disease, memory loss, dementia, senility, forgetful, geriatric, behavior, mood swings
High Dose Chemotherapy and Autologous Transplant for Breast Cancer

Study Overview
=================
Brief Summary
-----------------
To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy

Official Title
-----------------
High Dose Chemotherapy and Peripheral Blood Progenitor Cell Rescue for Patients With Breast Cancer

Conditions
-----------------
Graft vs Host Disease

Intervention / Treatment
-----------------
* Procedure: high dose chemo and auto hematopoietic cell transplant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stage II, III or IV breast cancer chemosensitive adequate organ function Exclusion Criteria: prior transplant, life threatening disease brain metastases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: high dose chemo and auto hematopoietic cell transplant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic Graft vs Host Disease
Patient Satisfaction After Eyelid Lesion Excision

Study Overview
=================
Brief Summary
-----------------
eyelid lesion excision is a common eyelid procedure. It associated with visual, aesthetic and functional changes .Investigator will evaluate patient satisfaction.

Detailed Description
-----------------
A baseline and 3 months full ophthalmic examination was done. Procedure is eyelid lesion excision. Satisfaction questionnaire concerning the functional and psychosocial impact of their eyelids was applied.

Official Title
-----------------
Patient Satisfaction After Different Surgical Techniques of Eyelid Lesion Excision

Conditions
-----------------
Eyelid Diseases

Intervention / Treatment
-----------------
* Procedure: eyelid lesion excision


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: eyelid lesion Exclusion Criteria: previous eyelid surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: eyelid lesion excision|eyelid lesion excision was done under local anesthesia|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| global aesthetic scale | calculate scale score from score 1 exceptional improvement to 5 worsening patient | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
eyelid, excision